Foot-and-mouth disease virus (FMDV) causes a highly contagious disease of cloven-hoofed animals. Vaccines require *7 days to induce protection; thus, before this time, vaccinated animals are still susceptible to the disease. Our group has previously shown that swine inoculated with 1 · 10 11 focus forming units (FFU) of a replication-defective human adenovirus containing the gene for porcine interferon alpha (Adt-pIFN-a) are sterilely protected from FMDV serotypes A24, O1 Manisa, or Asia 1 when the animals are challenged 1 day postadministration, and protection can last for 3-5 days. Polyriboinosinic-polyribocytidylic acid stabilized with poly-l-lysine and carboxymethyl cellulose (poly ICLC) is a synthetic double-stranded RNA that is a viral mimic and activates multiple innate immune pathways through interaction with toll-like receptor 3 and MDA-5. It is a potent inducer of IFNs. In this study, we initially examined the effect of poly IC and IFN-a on FMDV replication and gene induction in cell culture. Poly ICLC alone or combined with Adt-pIFN-a was then evaluated for its therapeutic efficacy in swine against intradermal challenge with FMDV A24, 1 day post-treatment. Groups of swine were subcutaneously inoculated either with poly ICLC alone (4 or 8 mg) or in combination with different doses of Adt-pIFN-a (2.5 · 10 9 , 1 · 10 9 , or 2.5 · 10 8 FFU). While different degrees of protection were achieved in all the treated animals, a dose of 8 mg of poly ICLC alone or combined with 1 · 10 9 FFU of Adt-pIFN-a was sufficient to sterilely protect swine when challenged 24 h later with FMDV A24. IFN-stimulated gene (ISG) expression in peripheral blood mononuclear cells at 1 day post-treatment was broader and higher in protected animals than in nonprotected animals. These data indicate that poly ICLC is a potent stimulator of IFN and ISGs in swine and at an adequate dose is sufficient to induce complete protection against FMD.
Introduction
F oot-and-mouth disease (FMD) is a severe, highly contagious disease of cloven-hoofed animals that is caused by a member of the Aphthovirus genus of the Picornaviridae family. The disease has a significant economic impact on affected countries. Currently, FMD is controlled by restriction of animal movement, slaughter of infected and in-contact susceptible animals, and in enzootic countries vaccination with an inactivated whole virus vaccine (Grubman and Baxt 2004) . However, administration of this vaccine or an experimental vaccine based on a replication-defective human adenovirus (Ad5) vector that delivers the FMD virus (FMDV) capsid and 3C proteins requires *7 days to induce protective immunity in animals (Moraes and others 2003; Golde and others 2005; Pacheco and others 2005) . Since FMDV replicates and spreads rapidly, we have focused on developing strategies that induce the innate immune response as a mechanism to initiate protection before the development of vaccine-induced adaptive immunity. This approach can also aid in the generation of a more robust and long-lasting adaptive immune response (Le Bon and others 2001; Cull and others 2002; Proietti and others 2002; Moraes and others 2003; de Avila Botton and others 2006) .
Type I interferon (IFN-a/b) is the first line of host defense against a viral infection, and it plays an important role in antiviral innate immunity (Stark and others 1998; Goodbourn and others 2000) . Induction and secretion of this cytokine by virally infected cells up-regulates hundreds of IFN-stimulated genes (ISGs) and their products, resulting in potent antiviral and immunomodulatory activity (Der and others 1998; Takaoka and Yanai 2006) . Previous studies by our group have shown that swine inoculated intramuscularly (IM) at 1 site in the hind limb with an Ad5 vector containing porcine IFN-a (Ad5-pIFN-a) are completely protected when challenged 1 day later either by intradermal (ID) inoculation or by direct contact with FMDV serotype A24 Cruzeiro (Chinsangaram and others 2003; Moraes and others 2003; Dias and others 2011) . Furthermore, protection lasts for 3-5 days, and even treatment 1 day postchallenge (dpc) reduces viremia and clinical disease as compared with control animals (Moraes and others 2003) . More recently, we demonstrated that Ad5-pIFN-a is also able to protect swine against challenge with a number of other FMDV serotypes, including O1 Manisa and Asia-1, and Ad5-pIFN-b protects against FMDV A24 challenge (Dias and others 2011). Moreover, we have also demonstrated that inoculation of cattle with an Ad5 vector containing a member of the bovine type III IFN family (Ad5-pIFN-l3) can protect 1 of 3 animals and significantly delay disease onset in the other 2 animals in the group challenged by aerosol 1 day later (Perez-Martin and others 2012). Thus, treatment with IFN has proved, so far, to be the best biotherapeutic approach tested against FMDV.
A commercially viable biotherapeutic approach or vaccine to block the spread of an animal pathogen should be economically affordable. Therefore, we have attempted to enhance the potency of our Ad5-IFN approach in several ways including (1) administration IM at 4 sites in the neck reduced the protective dose 10-fold as compared with our initial protocol that involved IM inoculation in the right hind limb (Dias and others 2011) , (2) subcutaneous (SC) rather than IM inoculation at 4 sites resulted in a 20-fold lower protective dose (Grubman and others 2012) , and (3) initiated studies to understand the molecular mechanisms induced by IFN treatment that result in protection against FMDV challenge and found a correlation between protection and both specific ISG up-regulation and tissue-specific infiltration of dendritic cells and natural killer (NK) cells (Moraes and others 2007; Diaz-San Segundo and others 2010) .
Poly ICLC is a synthetic, double-stranded polyriboinosinicpolyribocytidylic acid molecule stabilized with poly-l-lysine and carboxymethyl cellulose (poly ICLC) that has enhanced biostability in animals as compared with poly IC (Nordlund and others 1970) and is a known toll-like receptor 3 (TLR3) and MDA-5 agonist (Meylan and Tschopp 2006; Stahl-Hennig and others 2009) . In rodents and primates, poly ICLC is a strong IFN-a inducer that provides antiviral and adjuvant activity (Levy and others 1976; Harrington and others 1979; Caskey and others 2011) . It has been effective in providing protection in various animal models against a number of viral infections, including those caused by yellow fever, Venezuelan equine encephalomyelitis, Rift Valley fever, influenza, papilloma, and rabies viruses (Houston and others 1976; others 1977, 1979; Baer and others 1979; Kende and others 1985, 1987; Stahl-Hennig and others 2009; Li and others 2011) . Moreover, 2 intranasal (IN) doses of poly ICLC (8 and 48 h before infection) protected mice against IN challenge with a lethal dose of influenza and was found to be more efficacious than 2 IN doses of IFN-a or IFN-g (Wong and others 1995) . Likewise, the duration of protection against influenza virus provided by poly ICLC or liposome encapsulated poly ICLC in mice can persist for approximately 2 or 3 weeks post-treatment, respectively, although poly ICLC was less effective in the postexposure treatment of influenza virus infection than it was for prophylaxis (Wong and others 1995 (Wong and others , 2007 (Wong and others , 2009 . The antiviral activity of poly ICLC is related to its ability to modulate the immune response by inducing the production of IFNs, a, b, and l in vitro and in vivo (Levy and others 1975; Kende 1985; Lauterbach and others 2010) and by stimulating specific components of the cellular and humoral immune systems, including the activation of NK cells (Wiltrout and others 1985) . By inducing proinflammatory cytokines, poly ICLC up-and down-regulates a broad variety of cellular genes (Geiss and others 2001; Stahl-Hennig and others 2009; Caskey and others 2011) .
In the current study we examined the ability of poly ICLC alone or in combination with Ad5-pIFN-a (designated AdtpIFN-a) to inhibit FMDV replication in cell culture and to protect swine against FMDV challenge. Initially, we found that treatment of porcine and bovine cells lines with poly IC significantly reduced FMDV replication. Interestingly, in bovine cells, the combination of poly IC and bovine IFN (bIFN)-a had a synergistic effect as compared with each treatment alone, and there was up-regulation in the expression of a number of cytokines, chemokines, transcription factors, and genes with direct antiviral activity. Based on these results, we performed 2 animal studies in which different doses of Adt-pIFN-a and poly ICLC were combined and evaluated for efficacy against ID challenge with FMDV serotype A24 Cruzeiro. Our results indicate that 8 mg of poly ICLC is able to protect swine against FMDV A24 challenge when used alone or combined with 1 · 10 9 focus forming units (FFU) of Adt-pIFN-a. At lower individual or combination doses, some animals were protected, while others had a delay in disease onset and reduced disease severity and viremia as compared with controls. A broader array of up-regulated ISGs was detected in the peripheral blood mononuclear cells (PBMCs) of protected animals in comparison with animals partially protected. These results suggest that the use of TLR and/or cytosolic agonists alone or in combination with IFNs may represent an effective and broad-spectrum antiviral strategy that combats FMDV infection and perhaps other viral diseases of livestock species.
Materials and Methods

Cells and viruses
Baby hamster kidney cells (BHK-21, clone 13) were used to measure FMDV titers in plaque assays, and a swine kidney cell line (IB-RS-2) was used to measure antiviral activity in plasma from inoculated animals by a plaque reduction assay (Chinsangaran and others 2001). Embryonic bovine kidney (EBK) cells, LF-BK cells, a bovine kidney cell line (Swaney 1988) , and SK6 cells, a swine kidney cell line, were used to test the antiviral activity of poly IC, bIFN-a, and pIFN-a against FMDV serotype A12. EBK cells treated with different concentrations of poly IC and bIFN-a were also analyzed for up-regulation of ISGs. FMDV serotype A24 Cruzeiro was obtained from the vesicular fluid of infected swine, titered in both swine and in tissue culture, stored in aliquots at -70°C, and used for the swine challenge studies.
The replication-defective human Ad5 vector containing the pIFN-a gene, constructed as previously described (Gall and others 2007) and the control vector AdNull were obtained from GenVec, Inc. through an agreement with the Department of Homeland Security, Office of Science and Technology. The pIFN-a gene was supplied by our lab to GenVec, Inc. for use in the construction of the Ad5 vector containing type I IFN (designated Adt-pIFN-a). All experiments were performed with the same vector lot. Poly ICLC was provided by Oncovir, Inc.
Production of IFN and antiviral activity from in vitro samples IB-RS-2 cells in a T-75 flask were infected with either Ad5-pIFN-a or Ad5-bIFN-a at a multiplicity of infection (moi) of 20 for 24 h. The supernatant, containing p/bIFN-a, was removed, centrifuged at 2,500 rpm to remove cell debris, and filtered through an Amicon Ultra 100K centrifugal filter (Millipore Corp.) at 2,500 rpm for 30 min in a Sorvall centrifuge. The filtered supernatant was aliquoted and stored at -70°C. IB-RS-2 cells were treated with dilutions of p/bIFN-a for 24 h and subsequently infected with *100 plaque forming units (PFU) of FMDV A12. Antiviral activity, U/mL, was reported as the reciprocal of the highest supernatant dilution that resulted in a 50% reduction in the number of plaques relative to the number of plaques in the mock-treated infected cells.
EBK, LF-BK, or SK6 cells were treated with various concentrations of poly IC, bIFN-a, or pIFN-a, (the IFNs derived from the supernatants of IB-RS-2 cells infected with Ad5-bIFN-a or Ad5-pIFN-a, respectively, and titrated for antiviral activity) for *24 h, the media were removed, and the cells were washed 1 · with minimal essential medium (MEM; Gibco BRL, Invitrogen) and infected at different times posttreatment with FMDV A12 at an moi of 1. At 1 hour post infection (hpi), the media were removed, cells were washed once with 2-(N-morpholino) ethanesulfonic acid buffer (MES; pH 6) to inactivate nonadsorbed virus, once with MEM, followed by incubation in MEM for *20-24 h. Cells were frozen and thawed 1 · , centrifuged, and supernatants were collected to determine virus yield in BHK-21 cells by a standard plaque assay (Chinsangaram and others 1999) . Results were expressed as log 10 /mL of sample.
Animal studies
Two independent swine experiments were performed under a protocol reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Plum Island Animal Disease Center. Yorkshire pigs weighing about 35-40 lbs each were used in all experiments and acclimated for 5 days before the start of the experiments. Based on previous studies (Dias and others 2011), we selected an FMDV A24 Cruzeiro challenge dose of 10 5 TCID 50 for both experiments that is 10-fold higher than the challenge dose recommended by the World Organization of Animal Health (OIE) (OIE 2004) to be certain that the control animals develop clinical disease.
Three swine per group were inoculated SC with 2 mL Adt vector and/or poly ICLC (0.5 mL per site) in 4 sites in the neck. In the first experiment, animals were treated with either 2.5 · 10 9 FFU of Adt-pIFN-a or 4 mg of poly ICLC alone or in combination. For the second experiment, different dose combinations were used: 2.5 · 10 9 FFU or 1 · 10 9 FFU of AdtpIFN-a combined with 4 mg of poly ICLC; 1 · 10 9 FFU or 2.5 · 10 8 FFU of Adt-pIFN-a combined with 8 mg of poly ICLC; and 8 mg of poly ICLC alone. Swine inoculated SC with 2.5 · 10 9 FFU of AdNull were used as a control for both experiments. Adt-pIFN-a and/or poly ICLC inoculated animals were housed in double-gated rooms (2 animals per room) so that they had no direct contact, while the control group (AdNull) was housed together.
All animals were challenged ID at 1 day postinoculation (dpi) with FMDV A24 Cruzeiro, using 4 sites of inoculation in the hind heel bulb, 100 mL per site. The animals were monitored daily for 10 days for clinical signs, including fever, alertness, lameness, and development of vesicles on the coronary band of the hooves, snout, and mouth. Lesion scores of the animals were determined by the number of digits (16) plus snout and mouth with vesicles (maximum score is 17).
Blood and nasal swab sampling
Blood samples were drawn from the anterior vena cava at the times indicated in each experiment. Serum was obtained from blood drawn into nonheparinized tubes and tested for viremia and neutralizing antibodies using a standard plaque reduction assay as described below. Plasma was obtained from the blood drawn into heparinized tubes at 0, 1, and 2 dpi for an analysis of antiviral activity or at 0, 1, 2, and 4 dpi for extraction of RNA from PBMCs for an analysis of the expression of several ISGs (see next). Nasal swabs were collected starting the day of challenge and for the next 7 days and tested for the presence of FMDV by titration in BHK-21 cells.
IFN biological assays
Antiviral activity was evaluated in plasma samples as previously described (Moraes and others 2003; de Avila Botton and others 2006) . Briefly, samples obtained at 0-4 dpi were diluted and incubated on IB-RS-2 cells and after 24 h, supernatants were removed, and the cells were infected for 1 h with *100 PFU of FMDV serotype A12 and then overlaid with gum tragacanth. Plaques were visualized 24 h later by staining with crystal violet. Antiviral activity (U/mL) was reported as just described.
IFN-a ELISA
ELISA was performed as previously described (Moraes and others 2003) . Porcine IFN-a concentrations were expressed in picograms per milliliter and calculated by linear regression analysis of a standard curve generated with serial 2-fold dilutions of recombinant pIFN-a (PBL Biomedical Laboratories). All samples were assayed in duplicate. Serum levels of pIFN-a protein of < 200 pg/mL were considered background.
Detection of FMDV RNA by real-time reverse transcription-polymerase chain reaction
One to 7 dpc frozen sera samples from animals that had no detectable clinical disease were thawed and processed for RNA extraction and real-time reverse transcriptionpolymerase chain reaction (rRT-PCR) as previously described (Arzt and others 2010). Samples were considered positive when Ct values were < 40.
Plaque reduction neutralization (PRN 70 ) assay
Sera samples were collected at 0, 7, 14 and 21 dpc for each experiment, heated at 56°C for 30 min, and stored at -70°C. The presence of neutralizing antibodies against FMDV was determined in a plaque reduction neutralization (PRN) assay (Mason and others 1997) . Neutralizing titers were reported 464 DIAS ET AL.
as the serum dilution yielding a 70% reduction in the number of plaques (PRN 70 ).
3ABC ELISA assay
Swine sera from 0 and 21 dpc were examined for the presence of antibodies against FMDV nonstructural (NS) protein 3ABC using a PrioCHECKÔ FMDV-NS ELISA kit (Prionics AG) following the manufacturer's instructions (Sorensen and others 1998) .
Radioimmunoprecipitation of [ 35 S]methionine/[ 35 S]cysteine-labeled FMDV A24 infected cell lysates
In order to investigate the presence of antibodies specific to FMDV structural and NS proteins, lysates of FMDV A24 infected BHK-21 cells were incubated with convalescent serum from an FMDV infected bovine or individual swine sera samples from 0 and 21 dpc (Grubman and others 1984) . After 60 min of incubation at room temperature, antibodies were precipitated with Streptococcus aureus protein A. Proteins were resolved by SDS-PAGE on a 15% gel and visualized by autoradiography.
Analysis of ISGs
Total RNA was isolated from EBK cells using an RNeasy isolation kit (Qiagen) following the manufacturer's directions. RNA yield and quality was determined in a NanoDrop 1000 spectrophotometer (Thermo Fisher) and in a Bioanalyzer (Agilent Technologies). A quantitative rRT-PCR (qrRT-PCR) assay was used to evaluate the mRNA levels of a number of bovine genes as previously described (de los Santos and others 2006). Glyceraldehyde-3-phosphate dehyrogenase (GAPDH) was used as the internal control to normalize the values of each sample. Primer and probe sequences used are listed in Supplementary Table S1 (Supplementary Data are available online at www.liebertpub.com/jir). Reactions were performed in an ABI Prism 7000 sequence detection system (Applied Biosystems). Relative mRNA levels were determined by comparative cycle threshold analysis (user bulletin 2; Applied Biosystems) using mock-treated cells as a reference. We only considered genes up-regulated if there was a 2-fold or greater induction.
PBMCs were purified from heparinized blood and RNA extracted as previously described (Diaz-San Segundo and others 2010). A qRT-PCR was used to evaluate the mRNA levels of a number of ISGs utilizing as a reference the 0 dpi samples for each animal. The primer and probe sequences used to analyze swine gene up-regulation are listed in Supplementary Table S2 .
Results
Effect of poly IC or bIFN-a on FMDV replication in cell culture
EBK cells were treated for *24 h with various amounts of poly IC or bIFN-a alone or in combination and then infected with FMDV in the absence of the inhibitors. Virus yield was determined at 24 hpi. As shown in Table 1 , increasing a Each reagent or combination was diluted in 1 mL MEM and added to 1 · 10 6 cells. SD, standard deviation; FMDV, foot-and-mouth disease virus; EBK, embryonic bovine kidney; MEM, minimal essential medium; PFU, plaque forming units; bIFN, bovine interferon. amounts of either poly IC or bIFN-a resulted in an increased inhibition of FMDV yield. We repeated the experiment a number of times with both EBK cells and a bovine cell line, LF-BK cells, and obtained similar results, although the degree of inhibition varied (data not shown). Treatment of a swine cell line, SK6 cells, with various amounts of pIFN-a and poly IC also significantly reduced the yield of FMDV (Table 1) . We obtained similar results with pIFN-a in a second swine cell line, IB-RS-2 cells (data not shown).
To examine whether the combination of poly IC and bIFN-a could synergistically inhibit FMDV replication, we chose concentrations of each reagent that alone only had a limited effect on virus yield. The combination had a significant synergistic inhibitory effect in reducing FMDV yield in EBK cells at least 100-fold in comparison with poly IC or bIFN-a alone (Table 1) . Surprisingly, although there was a dose response with either poly IC or pIFN-a, we did not see a synergistic effect with the combination in the SK6 swine cell line.
We next examined the duration of protection afforded by either poly IC or bIFN-a. EBK cells were treated with various amounts of either molecule for 24 h, the media were removed, and cells were infected with FMDV immediately (1 day post-treatment) or at 1, 2, or 3 days after drug removal (2, 3 or 4 dpi) (Fig. 1) . The level of inhibition was dose dependent and lasted for at least 4 days after treatment with poly IC at all doses tested. Likewise, after treatment with bIFN-a, FMDV replication was reduced for at least 2 days, although at high amounts, that is, 50 U/mL, inhibition was maintained for at least 4 days.
Identification of ISGs induced in vitro
EBK cells were treated with different concentrations of bIFN-a (1-100 U/mL), poly IC (1.25-5.0 ng/mL), or the combination. RNA was analyzed for up-regulation of ISGs by qRT-PCR (Table 2) . In EBK cells treated with different concentrations of poly IC a broader array of ISGs was induced as compared with cells treated with different concentrations of bIFN-a. In addition, at all concentrations of poly IC used, there was an up-regulation of type I and III IFNs, but not at any concentration of IFN (Table 2) . Furthermore, the combination of poly IC and bIFN-a did not result in a synergistic up-regulation of these ISGs, but rather reflected the level of induction after poly IC treatment. We obtained very similar results in poly IC treated SK6 cells (manuscript in preparation).
Effect of pretreatment of swine with poly ICLC, Adt-pIFN-a, or the combination on resistance to FMDV challenge in swine Earlier, we demonstrated that IM inoculation at 4 sites in the neck with 1 · 10 10 FFU of Adt-pIFN-a protected swine against challenge with FMDV A24 Cruzeiro at 1 dpi (Dias and others 2011) . However, this is still a relatively high dose. In an attempt to lower the protective dose further, we hypothesized that the use of a TLR and/or cytosolic receptor ligand alone or in combination with IFN may help. To address this hypothesis, we performed 2 experiments in swine using poly ICLC, a more stable derivative of poly IC (Levy and others 1975) . None of the animals inoculated with poly ICLC showed any site reaction nor was their appetite or behavior affected in contrast to previously reported data showing a local reaction and influenza-like symptoms in human volunteers inoculated with a lower dose of poly ICLC (Caskey and others 2011) . In the first experiment groups of 3 animals were administered either 2.5 · 10 9 FFU Adt-pIFN-a, 4 mg of poly ICLC, the combination of 2.5 · 10 9 FFU Adt-pIFN-a and 4 mg of poly ICLC, or 2.5 · 10 9 FFU AdNull (control group). All groups were challenged at 1 dpi with 10 5 TCID 50 FMDV A24. The control animals developed viremia, virus in nasal swabs, and clinical disease by 2 or 4 dpc ( Table 3 ). All the animals in the group treated with 2.5 · 10 9 FFU Adt-pIFN-a developed disease at 4 dpc, but it was less severe than in the control group. Both the level of viremia and virus in nasal swabs were 10-1,000-fold lower than in the control group. In the 4 mg poly ICLC-treated group, one of the animals, No. 43, did not develop clinical signs, nor had detectable viremia or virus in nasal swabs and was negative for FMDV NS protein 3ABC and FMDV by RT-PCR. However, despite the absence of antibodies against the NS protein 3D, which are indicative of challenge virus replication, this animal developed a low FMDV-specific neutralizing antibody response and low levels of antibodies against the viral structural proteins (Table 3 and Supplementary Fig. S1 ). Another animal in this group, No. 41, developed clinical signs by 4 dpc, but viremia was not detectable and virus in nasal swabs was 10-100-fold lower than in the controls. The third animal in this group, No. 42, died 3 days postchallenge from causes related to FMD, although it had no detectable viremia or virus in nasal swabs at 1 and 2 dpc (Table 3 ). In the group given the combination treatment, 2 of the 3 animals, No. 36 and 37, did not develop clinical disease, viremia, or virus in nasal swabs, while the third animal, No. 35, only developed clinical disease at 7 dpc. These animals developed the highest levels of antiviral activity and pIFN-a protein in the blood. The two clinically protected animals in this group were negative by 3ABC ELISA, RT-PCR and had very low levels of FMDVspecific neutralizing antibodies, but had no detectable antibodies against either the viral structural proteins or 3D by radioimmunoprecipitation (RIP), indicating that they were either sterilely protected or had a very low level of challenge virus replication (Table 3 and Supplementary Fig. S1 ).
Based on the results of this experiment, we performed a second experiment lowering the Adt-pIFN-a dose and increasing the poly ICLC dose. Groups of 3 swine were inoculated with (1) 2.5 · 10 9 FFU and 4 mg of poly ICLC, (2) 1 · 10 9 FFU Adt-pIFN-a and 4 mg of poly ICLC, (3) 1 · 10 9 FFU and 8 mg of poly ICLC, (4) 2.5 · 10 8 FFU Adt-pIFN-a and 8 mg of poly ICLC, (5) 8 mg of poly ICLC alone, or (6) 2.5 · 10 9 AdNull. Animals were challenged 24 h later with 10 5 TCID 50 of FMDV A24 (Table 3 ). All control animals developed clinical disease by 2 dpc and high levels of viremia by 1-2 dpc (Table 3) . As in the previous experiment 2 of 3 animals in the group given 2.5 · 10 9 FFU Adt-pIFN-a and 4 mg of poly ICLC, No. 76 and 77, did not develop clinical disease, viremia, or virus in nasal swabs and were either sterilely protected or had very low levels of challenge virus replication, that is, negative 3ABC ELISA, RT-PCR and RIP, and undetectable or very low levels of FMDVspecific neutralizing antibody. The third animal in this group, Antiviral activity (U/mL) of swine plasma in IB-RS-2 cells and pIFN-a (pg/mL) detected in swine plasma by ELISA at 1 dpi.
c First dpc that viremia was detected; maximum amount of viremia in PFU/mL detected in sera samples; and the duration (days) of viremia.
d First dpc that shedding virus was detected; maximum amount of shedding virus in PFU/mL detected in nasal swab samples; and the duration (days) of shedding.
e dpc first signs of lesions/highest lesion score.
f Neutralizing antibody response of 21 dpc serum reported as serum dilution yielding a 70% reduction in the number of plaques (PRN 70 ).
g
Twenty-one dpc sera tested; N, negative; P, positive.
h
One to 7 dpc sera tested; N, negative; P, positive; ND, not done. Animal No. 87 died from non-FMD causes at 1 dpc. FFU, focus forming unit; Adt-pIFN-a, adenovirus containing the gene for porcine interferon alpha; dpi, day postinoculation; RT-PCR, reverse transcription-polymerase chain reaction; PRN, plaque reduction neutralization; NS, nonstructural; RIP, radioimmunoprecipitation; dpc, day postchallenge; SP, structural proteins; poly ICLC, polyriboinosinic-polyribocytidylic acid stabilized with poly-l-lysine and carboxymethyl cellulose.
No. 75, developed clinical signs 2 days later than the control animals, and the disease was less severe. When the dose of Adt-pIFN-a was decreased to 1 · 10 9 FFU and 4 mg of poly ICLC was added, all the animals developed clinical disease, but there was a delay of 2-4 days compared with the controls. One animal in this group, No. 78, never developed viremia or virus in nasal swabs, while the other 2 animals, No. 79 and 80, had 100-fold lower levels of viremia as compared with the controls. All the animals in the group administered 1 · 10 9 FFU Adt-pIFN-a and 8 mg of poly ICLC were sterilely protected. There was no evidence of virus replication by 3ABC ELISA, RT-PCR, and no detectable FMDV-specific neutralizing antibody response. Furthermore, the RIP gel analysis showed no evidence of antibodies against the viral structural proteins or the NS protein 3D supporting the absence of any detectable challenge virus replication (Table 3 and Supplementary Fig. S1 ). When the Adt-pIFN-a dose was reduced to 2.5 · 10 8 FFU, 1 animal, No. 84, did not develop clinical disease, while in the other 2 animals, No. 85 and 86, disease was delayed 3 or 5 days and viremia was reduced 100 or 10,000-fold as compared with the control group. In the group given only 8 mg of poly ICLC 1 animal, No. 87, died of causes unrelated to FMD, while the other 2 animals, No. 88 and 89, had no clinical disease, viremia, or virus in nasal swabs, and were 3ABC ELISA and RT-PCR negative. However, very low levels of FMDV-specific neutralizing antibodies were detected, although no antibodies against the viral structural proteins and NS protein 3D were evident in the RIP assay, suggesting that they were either sterilely protected or only had very low levels of challenge virus replication.
IFN-a levels and antiviral activity in plasma
All animals were assayed for the presence of pIFN-a protein and antiviral activity in plasma. Animals treated with 2.5 · 10 9 FFU Adt-pIFN-a combined with 4 mg of poly ICLC showed higher antiviral activity and higher levels of pIFN-a protein in plasma at 1 day post-treatment than the other treatment groups, with the exception of animals, No. 79 and 82, in the groups treated with 1 · 10 9 FFU Adt-pIFN-a combined with 4 or 8 mg of poly ICLC, respectively (Table  3) . These levels are considerably lower than those previously found in swine inoculated with 1 · 10 10 FFU Adt-pIFN-a alone (Dias and others 2011) .
Identification of ISGs
In the second experiment, we also evaluated the effect of Adt-pIFN-a and poly ICLC treatment on the expression of 21 ISGs in PBMCs at 1 day post-treatment (Table 4 and Fig. 2) . We selected ISGs that have various functional roles. All treatments were able to up-regulate some ISGs. However, among all treatment groups, 1 · 10 9 FFU Adt-pIFN-a combined with 8 mg of poly ICLC induced a broader array and higher levels of ISGs (Fig. 2 and Table 4 ). In 2 of the protected animals in this group, 21 and 17 genes were up-regulated from 5-to 84 fold. RIG-I, ISG-15, OAS, IRF7, IP-10, MDA-5, CCL5, Mx1, and IFN-aR1 were the ISGs up-regulated in most protected animals.
Discussion
In previous swine studies, we demonstrated that direct delivery of IFN genes can induce up-regulation of several ISGs and rapidly protect animals against challenge with multiple serotypes of FMDV (Chinsangaram and others 2003; others 2003, 2007; Dias and others 2011; Diaz-San Segundo and others 2011; Perez-Martin and others 2012) . Nevertheless, this strategy is currently quite costly, because it requires relatively high levels of IFN delivered by a recombinant Ad5 vector.
During the course of a viral infection, several ''pathogen associated molecular patterns'' are recognized by specific pattern recognition receptors present in host cells (Medzhitov and Janeway 1998; Honda and Taniguchi 2006) . These interactions result in the induction of a broad array of innate immune pathways that ultimately lead to the expression of IFNs. However, by directly administering IFN, the hostpathogen interactions that usually occur during viral infection are bypassed. Recent studies have shown that the highly efficacious live-attenuated yellow fever vaccine induces a large number of innate immune pathways before the initiation of a broad and persistent adaptive immune response (Gaucher and others 2008; Querec and others 2009; Caskey and others 2011) . The administration of poly ICLC to human volunteers induces a very similar and extensive array of genes, representing 10 canonical innate immune pathways (Caskey and others 2011) .
We hypothesized that treatment of animals with a molecular mimic of virus infection, such as dsRNA, could induce a broader array of genes in comparison to IFN treatment alone, and could also activate a number of signaling molecules that may potentially result in a positive feedback induction of additional type I IFN (Marie and others 1998; Honda and Taniguichi 2006; Yoneyama and others 2005) . Furthermore, we postulated that a combination of type I IFN and dsRNA may induce a more robust and sustained innate response than either treatment alone.
In cell culture, we found that both IFN-a and poly IC inhibited FMDV replication, while the combination had a synergistic effect in bovine cells but not in swine cells. Interestingly, poly IC induced the up-regulation of all genes examined, including type I and III IFNs, in both bovine and swine cells (Table 2 , manuscript in preparation), while IFN-a mainly induced the up-regulation of genes that have direct antiviral activity, including INDO, ISG15, Mx1, OAS, and PKR as well as IRF1 and 7. Presumably, this effect is the result of the ability of poly IC, but not IFNs, to activate IRF7, which has a major role in the induction of type I IFN genes (Honda and others 2005; Honda and Taniguchi 2006) . Using mouse embryonic fibroblasts from IRF7 knockout mice, Honda and others (2005) demonstrated that IRF7 is the master regulator of type I IFN immune responses and after its involvement in activating the initial phase of type I IFN gene induction, it is subsequently up-regulated by type I IFN and plays a crucial role in the induction of additional IFN-b and various subtypes of IFN-a (Honda and Taniguchi 2006) .
Based on the in vitro experiments, we performed animal studies to examine the efficacy of various individual or combination treatments on rapid protection against FMDV challenge. We found that a combination of 1 · 10 9 FFU AdtpIFN-a plus 8 mg poly ICLC resulted in sterile protection as measured by the absence of viremia and virus in nasal swabs, negative 3ABC ELISA, RT-PCR, and RIP for both structural and NS proteins, and the absence of detectable FMDV-specific neutralizing antibodies. We obtained essentially similar results in the group inoculated with only 8 mg Genes up-regulated in the majority of protected animals from different groups. Light gray boxes indicate genes that qualified as up-regulated ( ‡ 2-fold induction).
PBMCs, peripheral blood mononuclear cells.
poly ICLC, although these animals developed a very low level of FMDV-specific neutralizing antibodies (1:8). Surprisingly, in the group given a 4-fold lower dose of AdtpIFN-a, 2.5 · 10 8 FFU, plus 8 mg poly ICLC, only 1 animal was clinically protected and developed a low neutralizing antibody response (1:8), while the other 2 animals developed disease 3 or 5 days after the control animals. Although we do not have a clear explanation about these later results, we believe that the individual animal response is an uncontrolled factor that has to be taken into account. Different degrees of protection including delay in disease onset and less severe clinical signs were obtained with all the other combinations tested.
We examined gene induction at 1 dpi in PBMCs of treated swine. The pattern of gene induction followed the degree of protection. The group with the highest number of upregulated genes was the group inoculated with 1 · 10 9 FFU Adt-pIFN-a plus 8 mg poly ICLC in which all animals were protected against challenge. This group was followed by the 8 mg poly ICLC group in which all animals were also protected ( Fig. 2 and Table 4 ). The groups in which 2 of 3 or 1 of 3 animals were protected had the next highest number of genes induced, while the group in which all the animals developed clinical disease, but lesions were detected 2-4 days later than the control animals had more genes induced than the control group. Some genes were up-regulated in all, RIG-I and ISG15, or most of the protected animals, IRF7, IP-10, OAS, MDA-5, Mx1, CCL5, and IFN-aRI, but were also induced in some unprotected animals. We have previously shown that OAS and PKR have a role in the inhibition of FMDV replication (Chinsangaram and others 2001; de los Santos and others 2006) , and we found that in tissues of swine inoculated with Ad5-pIFN-a and Ad5-pIFN-g or bovines inoculated with Ad5-bIFN-l, there was an induction of IP-10 and these animals had increased numbers of DCs and NK cells in the skin and lymph nodes others 2010, 2011) .
It is difficult to directly correlate protection with gene induction, as we only analyzed a very limited number of genes and examined gene induction only in PBMCs. Nevertheless, the cell culture and animal data indicate that poly ICLC induces a broader array of genes than IFN. While both IFN and poly ICLC pretreatment can protect swine as early as 1 day postadministration, the utility of an animal biotherapeutic approach requires the protective dose to be affordable. Combining Adt-pIFN-a and poly ICLC as well as altering the route and number of sites of inoculation have allowed us to use a 100-fold lower dose of the Adt vector as compared with our initial studies (Dias and others 2011) . In addition, even in the group given a 4-fold lower dose of Adt vector, 2.5 · 10 8 FFU, and poly ICLC, 1 animal was protected while the other 2 animals only developed lesions 3 or 5 days later than the control inoculated animals, and the level of viremia was reduced by 100-10,000-fold. Since our goal is to combine biotherapeutics with an FMD vaccine, even this lower dose of Adt-pIFN-a appears to be sufficient to delay disease onset until the vaccine-induced adaptive response is effective (Grubman 2003) .
Our results indicate a viral mimic, such as poly ICLC, administered with IFN, and the FMD vaccine may represent a successful and more economical approach in providing rapid and long-lasting protection in animals against this feared disease.
